Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1623 1673 1693 1773
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19443682 | COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ACIDS OR FATTY ESTERS FORMULATED WITH AN AMIDE-BASED NEUTRAL SURFACTANT | Final Rejection | INTEGRITY BIO-CHEMICALS, LLC |
| 18285789 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Non-Final OA | Emory University |
| 18359435 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 18570695 | ORGANOPOLYSILOXANE-MODIFIED CYCLODEXTRIN COMPOUND, METHOD FOR PRODUCING SAME, AND COSMETIC CONTAINING SAME | Non-Final OA | SHIN-ETSU CHEMICAL CO., LTD. |
| 18573684 | METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18699983 | SHORT AMORPHOUS CELLULOSE POLYMERS | Non-Final OA | Katholieke Universiteit Leuven |
| 18547932 | COMPOSITIONS AND METHODS USING A COMBINATION OF OLEUROPEIN AND VITAMIN B6 | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18331536 | Novel Synthesis of Phosphorodithioate Oligonucleotides | Non-Final OA | Hoffmann-La Roche Inc. |
| 18150553 | Process for the preparation of oligonucleotides using modified oxidation protocol | Final Rejection | Hoffmann-La Roche Inc. |
| 18542500 | NUCLEOSIDE-5'-OLIGOPHOSPHATES HAVING A CATIONICALLY-MODIFIED NUCELOBASE | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18379047 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18482334 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN FELINES | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy